RNAi therapeutic improves overall liver health in antitrypsin deficiency

RNAi therapeutic improves overall liver health in antitrypsin deficiency

Using a novel RNA interference therapeutic improved fibrosis and reduced toxic proteins and globular burden in alpha-1 antitrypsin deficiency, according to a presenter at the International Liver Congress.“AATD-associated liver disease is an inherited disease manifesting due to mutations in the alpha-1 antitrypsin, or AAT gene,” Pavel Strnad, MD, of the University Hospital Rwth Aachen in Aachen, Germany, said during his Late Breaker presentation. “The homozygous PiZZ mutation is the focus of today’s presentation is responsible for the majority of severe AATD cases.”Read More

Share on facebook
Share on twitter
Share on linkedin